FDAnews Drug Daily Bulletin

Transparency on Clinical Trials: Better Late Than Never? (World of DTC Marketing Blog)
“In an unprecedented move that could signal dramatic changes in the drug industry, GlaxoSmithKline is promising to make detailed data from its clinical trials available to independent researchers so that scientists can draw their own conclusions about the safety and effectiveness of its new drugs,” blogger Rich Meyer writes, comparing the move to putting water on an already extinguished flame. “While I applaud this idea by GSK I can only hope that this is an earnest move not a marketing gimmick.”